Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: October 2025 (Issued October 23, 2025)
Subject: Announcement of US FDA approval for Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and clinical data. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Clinical Milestones
- Regulatory Approval: The US FDA approved Blenrep in combination with BVd for patients with relapsed/refractory multiple myeloma (3L+ setting).
- Clinical Efficacy (DREAMM-7 Trial):
- Overall Survival: 51% reduction in the risk of death (HR 0.49) compared to a daratumumab-based triplet (DVd).
- Progression-Free Survival (PFS): Median PFS tripled to 31.3 months versus 10.4 months for the comparator.
- Market Differentiation: Blenrep is positioned as the only anti-BCMA agent accessible in the community setting, where approximately 70% of patients receive care, supported by a streamlined Risk Evaluation and Mitigation Strategy (REMS).
- Global Status: Combinations are already approved in the EU, UK, Japan, Canada, Switzerland, and Brazil. Applications are under review in China (granted Breakthrough Therapy Designation and Priority Review).
Guidance, Outlook, and Management Commentary
Management Commentary: Tony Wood, Chief Scientific Officer, stated the approval provides potential for superior efficacy and fulfills a major patient need for community-accessible treatment. The company aims to redefine treatment for multiple myeloma globally.
Future Outlook and Pipeline:
- Earlier Lines of Therapy: GSK is advancing development in earlier lines, including newly diagnosed patients.
- DREAMM-10 Trial: A Phase III trial in newly diagnosed transplant-ineligible patients was initiated in Q4 2024. Interim efficacy and safety data are expected in early 2028.
- Overall Survival Data: Follow-up for OS in DREAMM-7 and DREAMM-8 is ongoing, with data expected in early 2028.
- Guidelines: Data from the DREAMM programme will be submitted to the National Comprehensive Cancer Network (NCCN) guidelines in 2025.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in GSK's 2024 Form 20-F and Q2 2025 results. No specific new contingencies were detailed beyond standard regulatory and clinical development risks.
Key Facts for Investor Verification
- Verify the commercial launch timeline and reimbursement status for Blenrep in the US following the October 2025 approval.
- Monitor the enrollment progress and interim data release schedule for the DREAMM-10 trial (expected early 2028) to assess potential expansion into the first-line market.
- Track the submission and acceptance of DREAMM data into NCCN guidelines to gauge adoption rates among oncologists.
- Review the impact of the streamlined REMS programme on patient access and administrative burden compared to previous requirements.
- Confirm the status of the China application, which holds Priority Review designation, as a key growth market.